Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-25T09:08:42.488Z Has data issue: false hasContentIssue false
  • English
  • Français

A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity

Published online by Cambridge University Press:  02 January 2018

E. Goodall ,
Christine Oxtoby ,
Ray Richards ,
Gill Watkinson ,
David Brown  and
Trevor Silversonte
E. Goodall*
Affiliation:
Academic Unit of Human Psychopharmacology, Medical College of St Bartholomew's Hospital
Christine Oxtoby
Affiliation:
Hackney and Homerton Unit
Ray Richards
Affiliation:
Servier Reserach and Development, Fulmer, Slough
Gill Watkinson
Affiliation:
City and Hackney Health District
David Brown
Affiliation:
Medical College of St Bartholomew's Hospital, London
Trevor Silversonte
Affiliation:
Medical College of St Bartholomew's Hospital, London
*
∗St John's Wing, Homerton Hospital, Homerton Grove, London E9 6SR
Get access Rights & Permissions [Opens in a new window]

Abstract

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg d-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking d-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 153 , Issue 2 , August 1988 , pp. 208 - 213
Copyright
Copyright © Royal College of Psychiatrists, 1988 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Campbell, D. B. (1970) Gas chromatographic measurement of levels of fenfluramine and norfenfluramine in human plasma, red cells and urine following therapeutic doses. Journal of Chromatography, 49, 442–447.CrossRefGoogle ScholarPubMed
Campbell, D. B. (1971) Plasma concentrations of fenfluramine and its metabolite, norfenfluramine after single and repeated oral administration. British Journal of Pharmacology, 43, 465P.Google Scholar
Campbell, D. B. (1973) Absorption, distribution and metabolism of fenfluramine. La Vie Medicale au Canada Francais, 2, 34–40.Google Scholar
Davis, J. M. & Schlemmer, R. F. (1980) The amphetamine psychosis. In Amphetamine and Related Stimulants: Chemical, Biological Clinical and Sociological Aspects (ed. Caldwell, J.), pp 161–173. Florida: CRC Press.Google Scholar
Douglas, J. G., Preston, P. G., Haslett, C., Gough, J., Frazer, I., Chalmers, S. R. & Munro, J. F. (1983) Long-term efficacy of fenfluramine in treatment of obesity. The Lancet, i, 384–386.Google Scholar
Garattini, S. & Samanin, R. (1976) Anorectic drugs and brain neurotransmitters. In Appetite and Food Intake (ed. Silverstone, T.). Life Sciences Research Report No. 2, pp. 83–108. Berlin: Dahlem Konferenzen.Google Scholar
Garrow, J. S. (1981) Treat Obesity Seriously. Edinburgh: Churchill Livingstone.Google Scholar
Hossain, M. & Campbell, D. B. (1975) Fenfluramine and methyl-cellulose in the treatment of obesity: the relationship between plasma drug concentrations and therapeutic efficacy. Postgraduate Medical Journal, 51, suppl. 1, 178–182.Google Scholar
Innes, J. A., Watson, M. L., Ford, M. J., Munro, J. F., Stoddart, M. E. & Campbell, D. B. (1977) Plasma fenfluramine levels, weight loss and side effects. British Medical Journal, ii, 1322–1325.Google Scholar
Klein, B., Steele, R., Simon, W. E. & Primavera, L. H. (1972) Reinforcement and weight loss in schizophrenics. Psychological Reports, 30, 581–582.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Paul, A. A. & Southgate, D. A. T. (1978) McCance and Widdowson's The Composition of Foods. (4th edn). London: HMSO.Google Scholar
Preston, P. G., Ford, M. J. & Munro, J. F. (1979) Studies on fenfluramine as an anti-obesity agent. Current Medical Research and Opinion, 6, Suppl. 1, 188–193.Google Scholar
Royal College of Physicians (1983) Obesity. Journal of the Royal College of Physicians of London, 17, 6–65.Google Scholar
Scoville, B. A. (1973) Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgements. In Obesity in Perspective, Proceedings of the Fogarty Conference (ed. Bray, G.), pp 441–443. Washington: US Government.Google Scholar
Silverstone, T. & Goodall, E. (1984) The clinical pharmacology of appetite suppressant drugs. International Journal of Obesity, 8, suppl. 1, 23–33.Google Scholar
Silverstone, T., Smith, G. & Richards, R. (1987) A comparative evaluation of dextrofenfluramine and dl-fenfluramine on hunger, food intake, psychomotor function and side effects in normal human subjects. In Body Weight Control, the Physiology, Clinical Treatment and Prevention of Obesity (eds Bender, A. E. & Brookes, L. J.), pp 240–246. Edinburgh: Churchill Livingstone.Google Scholar
Silverstone, T., Smith, G. & Goodall, E. (1988) The prevalence of obesity in patients receiving depot antipsychotics. British Journal of Psychiatry, 153, 214–217.Google Scholar
Sletten, I., Mou, B., Cazenave, M. & Gershon, S. (1967) Effects of caloric restriction on behaviour and body weight during chlorpromazine therapy. Diseases of the Nervous System, 28, 519–522.Google Scholar
Stunkard, A. J., Craighead, L. W. & O'Brien, R. (1980) Controlled trial of behaviour therapy, pharmacotherapy and their combination in the treatment of obesity. The Lancet, ii, 1045–1047.Google Scholar
Wurtman, J., Wurtman, R., Mark, S., Tsay, R., Gilbert, W. & Growdon, J. (1985) D-fenfluramine selectively suppresses carbohydrate snacking by obese subjects. International Journal of Eating Disorders, 4, 89–99.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.